2020

News

  • European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19
  • IMU-838 is an orally available small molecule, which, because of its broad-spectrum antiviral effect and selective immunomodulatory properties, is currently being evaluated for the treatment of COVID-19
  • The EIB venture loan is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the European Union’s research and innovation program for 2014-2020

LUXEMBOURG and GRÄFELFING, Germany and NEW YORK, Oct. 20, 2020 /PRNewswire/ — The European Investment Bank (EIB) and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of a €24.5 million financing agreement. The venture loan is intended to support Immunic’s ongoing phase 2 CALVID-1 trial of its lead asset, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19). In addition, it is also intended to support the potential expansion of the CALVID-1 trial into a confirmatory phase 3 trial and the commercial-scale manufacturing for IMU-838. Immunic AG, the German subsidiary of Immunic, Inc., will receive the EIB loan in three tranches upon the completion of pre-defined milestones.

IMU-838, an orally available small molecule, has successfully demonstrated preclinical activity against SARS-CoV-2 in multiple assays and is currently undergoing a phase 2 clinical trial in hospitalized COVID-19 patients with moderate disease activity. IMU-838 is also being tested in other phase 2 trials evaluating the use of the drug as a potential treatment for chronic inflammatory and autoimmune diseases, such as multiple sclerosis or ulcerative colitis.

„While SARS-CoV-2 infections are on the rise, many of Europe’s top scientists are working relentlessly to help better control the pandemic,“ said Ambroise Fayolle, EIB Vice-President in charge of innovation and lending in Germany. „The role of European institutions is to support their research and innovation to the best of our ability. I am therefore very pleased that EIB financing can contribute to the R&D activities of Immunic. If successful, Immunic’s drug may reduce the number of critically ill COVID-19 patients, thereby relieving the burden on health systems, patients and families alike.“

Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth, said: „The European Union is actively involved in the worldwide race to find better solutions for the COVID-19 disease. With this loan to Immunic, we continue to accelerate the development of innovative treatments against coronavirus and other severe diseases faced by our society.“

„The funding commitment by the EIB is a confirmation of its faith in Immunic’s ability to advance our lead asset, IMU-838, a selective oral DHODH inhibitor, which has shown strong antiviral activity in preclinical testing, as a potential treatment for COVID-19,“ stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. „This investment will enable us to continue to advance our CALVID-1 clinical program and we look forward to reporting the results of a pre-planned interim efficacy analysis from the phase 2 trial later this year, after which we plan to evaluate whether the program may be expanded into a confirmatory phase 3 trial.“

One of Immunic’s goals is to develop IMU-838 not only as a treatment option for COVID-19, but also for potential use against other, future viral pandemics. The drug’s antiviral effect has been shown to be host-based, which suggests that it is independent of virus-specific proteins and their structure, shielding it from resistance or mutations of SARS-CoV-2, and also expanding its potential application to other viruses. For instance, IMU-838 has previously demonstrated activity in vitro against Influenza A virus, HIV, and Hepatitis C virus, amongst others. Importantly, IMU-838 has already been tested in about 650 individuals with an attractive pharmacokinetic, safety and tolerability profile, to date.

The EIB loan to Immunic is backed by the Infectious Diseases Finance Facility (IDFF) set up as part of the European Union’s Horizon 2020 Program. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through this facility, the EIB has supported European companies via total lending of about €400 million for developing cures, vaccines and diagnostics for various infectious diseases, most prominently coronavirus.

About the EIB
The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the European Union.

About the InnovFin Infectious Diseases Finance Facility
The InnovFin Infectious Diseases Finance Facility (IDFF) is dedicated to supporting the fight against infectious diseases. This joint European Commission and EIB Group initiative is part of Horizon 2020, the 2014-2020 EU research and innovation program. The IDFF enables the EIB to provide between €7.5 million and €75 million of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combating infectious diseases. The financing mainly goes to projects that have completed the preclinical stage and need clinical approval for further development. The IDFF has been increased by €400 million to boost its capacity for tackling the outbreak of the coronavirus. The total EU contribution to the IDFF via Horizon 2020 is estimated at almost €700 million.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. On August 2, 2020, Immunic announced positive top-line results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance, indicating activity for IMU-838 in this indication. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn’s disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains „forward-looking statements“ that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases; clinical data for IMU-838; the timing of current and future clinical trials; the potential for IMU-838 as a treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections associated with coronavirus disease 2019 (COVID-19) and any clinical trials, collaborations and approvals relating to such potential treatment; the future use of the EIB venture loan; the nature, strategy and focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned „Risk Factors,“ in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 3, 2020, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

EIB
Antonie Kerwien, a.kerwien@eib.org, tel.: +352 43 79 82175 / Mobile: +352 691 285 497
Website: www.eib.org/press – Press Office: +352 4379 21000 – press@eib.org

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Immunic, Inc. US IR Contact
Rx Communications Group
Melody Carey
+1 917 322 2571
immunic@rxir.com

Immunic, Inc. US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com

European Commission
Johannes Bahrke
+32 460 75 86 15
Johannes.BAHRKE@ec.europa.eu

Marietta Grammenou
+32 460 755021
Marietta.GRAMMENOU@ec.europa.eu

von tg

Die neugegründete IcanoMAB GmbH (Polling) hat eine Gründungsfinanzierung in ungenannter Höhe eingeworben, die ausreicht, einen COVID-19-Antikörperkandidaten weiterzuentwickeln.

Das frisch gegründete Unternehmen hat einen bis fast zur klinischen Reife finanzierten Anti-IL18-Corezeptor-Antikörper (IL-1R7) in der Pipeline, der den durch Interferon gamma inititierten Zytokinsturm bei COVID-19-Patienten im Spätstadium der Erkrankung verhindern soll. Bisher stammt das Geld von Stephan Fischer, CEO der MAB Discovery GmbH. Zwei weitere präklinische Antikörperkandidaten aus der Mab Discovery-Pipeline zielen auf Anwendungen in der Onkologie, Immunmodulation und bei akuten Entzündungen ab, insbesondere auf das Makrophagen-Aktivierungs-Syndrom, SJIA/ Still-Krankheit oder IBD und Gicht, der adjuvanten Brustkrebstherapie und in der Immunonkologie.

Fischer hatte zuletzt betont, dass eine öffentliche Förderung von COVID-19-Therapien dringend erforderlich sei, da noch nicht gesagt werden könne, ob und wie nebenwirkungsarm entsprechende Vakzinekandidaten verabreicht werden können. Aus Schweden ist ein Fall bekannt, bei dem Affen die schwere Nebenwirkung Antibody-directed Enhancement (ADE) nach Verabreichung eines Impfkandidaten zeigten, die das COVID-19-Syndrom dramatisch verschlimmert statt zu verbessern.

Nach Informationen von |transkript.de kann die klinische Prüfung mit einem Investment von 6 Mio. Euro binnen 12 Monaten erreicht werden, für den Konzeptbeweis würden 10 bis 15 Mio. Euro benötigt. Im vergangenen Jahr hatte MAB Discovery nach zehn Jahren seine Antikörperproduktion und sein Labor an die Mainzer BioNTech (NASDAQ: BNTX) verkauft. Ende 2019 wurde ein präklinisches Projekt im Bereich der Immunonkologie an ein Pharmaunternehmen lizenziert. IcanoMAB will den Erlös der Gründungsfinanzierung nun zur Weiterentwicklung der Pipelinekandidaten verwenden, um IND-aktivierende Aktivitäten und entsprechende Entwicklungspartnerschaften zu ermöglichen.

©transkript.de

NEW YORK, August 20, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy volunteer in the company’s phase 1 clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function. Based on preclinical data, the compound appears to represent a novel and paradigm-shifting approach to the treatment of gastrointestinal diseases by potentially restoring intestinal barrier function while maintaining immunocompetency. Immunic’s Australian subsidiary, Immunic Australia Pty Ltd., received clearance from the Bellberry Human Research Ethics Committee in Australia to begin a phase 1 trial of IMU-856 under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutic Goods Administration (TGA). The phase 1 clinical program includes single and multiple ascending dose parts in healthy volunteers. Subsequently, Immunic also plans to extend this program to assess biomarker, safety and drug trough levels in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), ulcerative colitis (UC) and Crohn’s disease (CD).

“Dosing of the first healthy volunteer in our phase 1 clinical program of IMU-856 brings us one step closer to evaluating whether our approach may eventually translate into a novel treatment option for patients suffering from a range of gastrointestinal diseases, by potentially restoring function of the intestinal barrier without impairing the immune system,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. “Based on strong preclinical data, IMU-856 shows significant therapeutic potential for diseases that are known to be triggered by the disruption of intestinal barrier function.”

The phase 1 study is a double-blind, randomized, placebo-controlled trial comprised of three parts. The first part is a single ascending dose portion in healthy volunteers, which is planned to be followed by a second, multiple ascending dose part in healthy volunteers, with IMU-856 given daily for 14 consecutive days. These first two parts of the phase 1 trial are designed to assess the safety, tolerability and pharmacokinetic properties of IMU-856. In a third part of the phase 1 trial, the study drug would be given daily over 28 consecutive days at two different dose levels in patients with IBS-D, UC and CD who were screened for increased bowel permeability using oral marker tests. The change in bowel permeability, using a 2-sugar test to monitor therapeutic effects, would be evaluated as a pharmacodynamic marker, and include a comparison of two active dose groups to placebo. Additionally, biomarker, safety and trough plasma concentration levels would also be assessed.

Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, noted, “Current treatments for many gastrointestinal conditions focus on inhibiting inflammation and do not directly address impaired intestinal barrier function. In contrast, IMU-856 appears to have a unique targeted ability to strengthen and thereby normalize this function, potentially avoiding the bacterial triggers which can occur when the intestinal barrier is impaired. Moreover, because this approach appears to avoid any detrimental effects on the immune system, we believe that IMU-856 has the potential to change the treatment paradigm for gastrointestinal diseases.”

IMU-856 was discovered and initially developed by Daiichi Sankyo Co., Ltd. (Daiichi Sankyo). In November 2018, Immunic and Daiichi Sankyo entered into a global option and license agreement, granting Immunic an exclusive global option to obtain the exclusive right to license a group of compounds, designated by Immunic as IMU-856. Under this agreement, Immunic has the rights to commercialization of IMU-856 in all countries, including the United States, Europe and Japan. The option also includes exclusivity on a patent application filed by Daiichi Sankyo, covering IMU-856’s composition of matter. Immunic exercised the option in January 2020.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. On August 2, 2020, Immunic announced positive top-line results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance, indicating activity for IMU-838 in this indication. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn’s disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s three development programs and the targeted diseases; the potential for IMU-838, IMU-935 and IMU-856 to safely and effectively target diseases; preclinical data for IMU-856; the timing of future clinical trials; the nature, strategy and focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 3, 2020, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

 

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
phone: +49 89 2080 477 09
e-mail: jessica.breu@imux.com

US IR Contact
Rx Communications Group
Melody Carey
phone: +1-917-322-2571
e-mail: immunic@rxir.com

US Media Contact
Speak Life Science, LLC
Amy Speak
phone: +1-617-420-2461
e-mail: amy@speaklifescience.com

Link zu Pressemitteilung

NEW YORK, August 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 750,000 shares.

Immunic received total proceeds from the offering, before deducting the underwriting discounts and other offering expenses, of $103.5 million. 

SVB Leerink acted as sole bookrunning manager for the offering. Wedbush PacGrow and Ladenburg Thalmann acted as co-managers for the offering.

The Company intends to use the net proceeds of the offering to fund the ongoing clinical development of its three lead product candidates, IMU-838, IMU-935 and IMU-856, including to investigate IMU-838 in a potential phase 3 program in relapsing-remitting multiple sclerosis, and for other general corporate purposes.

The securities described above were offered by Immunic, Inc. pursuant to a shelf registration statement filed by Immunic, Inc. with the Securities and Exchange Commission (SEC), which was declared effective on June 13, 2018. A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on August 5, 2020 and is available for free on the SEC’s website at www.sec.gov

Copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at syndicate@svbleerink.com, or by telephone at (800) 808-7525, ext. 6218.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function.  IMU-838 is in phase 2 clinical development for relapsing-remitting multiple sclerosis, ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn’s disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. 

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release regarding the offering, including the anticipated use of the net proceeds from the offering, strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management, including in relation to Immunic’s development programs, are forward-looking statements. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including those set forth in the sections captioned “Risk Factors” in Immunic’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this press release speaks only as of the date of this press release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

 

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
phone: +49 89 2080 477 09
e-mail: jessica.breu@imux.com

Or

Rx Communications Group
Melody Carey
phone: +1-917-322-2571
e-mail: immunic@rxir.com

Link zu Pressemitteilung

Die Software von incapptic Connect wird in MobileIrons Unified Endpoint Management (UEM)-Plattform integriert, so dass Business-Apps schneller entwickelt, bereitgestellt und abgesichert werden können.

München, 30. April 2020 – MobileIron übernimmt incapptic Connect, ein Unternehmen mit Sitz in Berlin und Warschau, das zu den führenden Anbietern von Software zur automatisierten Veröffentlichung von Business-Apps gehört. Die Integration der incapptic Connect Software in die UEM-Plattform von MobileIron ermöglicht die schnelle Entwicklung, Bereitstellung und Sicherung von unternehmensinternen Apps. Damit haben Kunden mehr Zeit für mehr Produktivität und Geschäftsinnovationen.

„Wir freuen uns, das Team von incapptic Connect in der MobileIron-Familie willkommen zu heißen.“, sagt Simon Biddiscombe, CEO von MobileIron. „Unternehmen wollen ihre digitalen Arbeitsplätze ausbauen, insbesondere wegen der Corona-Pandemie. Entsprechend steigt der Druck auf die IT-Teams, eigene Apps in kürzester Zeit zu entwickeln und bereitzustellen, damit die Produktivität des Unternehmens nicht darunter leidet. incapptic Connect hat ein hervorragendes Produkt entwickelt, das genau diesen Ansprüchen gerecht wird. Die Integration von incapptic Connect mit MobileIron-UEM vereinfacht der App-Release-Prozess weiter, damit Unternehmen ihre Sicherheits- und Produktivitätsstrategien zuverlässig umsetzen können.“

Gemeinsam unterstützen MobileIron und incapptic Connect ein Automatisierungsmodell für die Distribution von Apps. Die Software von incapptic Connect prüft selbstständig, ob eine App die notwendigen Voraussetzungen für den Launch in einem öffentlichen oder internen App-Store erfüllt. incapptic Connect automatisiert dann den Veröffentlichungsprozess. Sobald eine Anwendung gelauncht ist, verteilt MobileIron UEM sie auf verwaltete Geräte und steuert die Aktualisierungen, damit die Benutzer immer mit der sichersten und aktuellsten Version arbeiten.

„Wir freuen uns, Mitglied des MobileIron-Teams zu sein und Unternehmen dabei zu helfen, ihre App-Innovationen schneller und sicherer nutzen zu können.“, sagt Dr. Rafael Kobylinski, Gründer von incapptic Connect. „Der Entwicklungsprozess und die Bereitstellung maßgeschneiderter Apps ist meist mit hoher Komplexität und viel Zeitverschwendung verbunden. Die Kombination der incapptic Connect-Software mit MobileIron-UEM verschafft Unternehmen die Dynamik, um ihren Einfallsreichtum voll auszuschöpfen und geniale App-Ideen schnell wahr werden zu lassen.“

Native Business-Apps sind ein zentraler Bestandteil von digitalen Arbeitsplätzen. CIOs, CDOs und Fachbereiche aller Branchen entwickeln eigene Apps, um wichtige Geschäftsziele leichter zu erreichen, Mitarbeiter das bestmögliche Nutzererlebnis zu bieten und ihren Unternehmen Wettbewerbsvorteile zu verschaffen. Der Freigabeprozess von Unternehmens-Apps ist heute allerdings kompliziert: eine Vielzahl von externen Lieferanten, komplexe Genehmigungsprozesse und Anforderungen der App-Stores verzögern den Launch geschäftskritischer Apps oft um Wochen, wenn nicht sogar Monate. incapptic Connect strafft diesen Prozess und verkürzt die Zeit bis zur Bereitstellung auf Minuten oder nur wenige Stunden. In Kombination mit der UEM von MobileIron wird die zielgerichtete Distribution der Anwendungen an die befugten Benutzer und Geräte automatisiert. Auf diese Weise helfen MobileIron und incapptic Connect Unternehmen, ihre Initiativen für die Digitalisierung der Arbeitsplätze schnell und zuverlässig umzusetzen.

Organisationen können mit der MobileIron-UEM ihre digitalen Arbeitsplätze sicherer machen. Basis dafür sind die kennwortlose Benutzer- und Geräteauthentifizierung, genannt Zero-Sign-On (ZSO), Multi-Faktor-Authentifizierung (MFA) und Mobile Threat Defense (MTD).

Unternehmen und Organisationen können bis zum 15. Juni 2020 beliebig viele neue Benutzer und Geräte auf MobileIrons UEM-Plattform registrieren, und das ohne zusätzliche Kosten. Über diesen Link können Sie mehr erfahren oder sich für die bevorstehenden Webinare anmelden.

Über MobileIron
MobileIron definiert die Unternehmenssicherheit neu mit der branchenweit ersten mobilzentrierten Zero-Trust-Plattform, die auf der Grundlage von Unified Endpoint Management (UEM) aufgebaut ist, um den Zugriff auf und den Schutz von Daten im gesamten Unternehmen unbegrenzt zu sichern. Zero Trust setzt voraus, dass sich Cyberkriminelle bereits im Netzwerk befinden und der sichere Zugriff durch einen „never trust, always verify“-Ansatz bestimmt wird. MobileIron geht über Identitätsmanagement und Gateway-Ansätze hinaus, indem es einen umfassenderen Satz von Attributen verwendet, bevor der Zugriff gewährt wird. Ein mobilfunkzentrierter Zero-Trust-Ansatz validiert das Gerät, stellt den Benutzerkontext her, prüft die Autorisierung von Anwendungen, verifiziert das Netzwerk und erkennt und behebt Bedrohungen, bevor ein sicherer Zugriff auf ein Gerät oder einen Benutzer gewährt wird.

Die MobileIron-Sicherheitsplattform basiert auf der Grundlage der preisgekrönten und branchenführenden Unified Endpoint Management (UEM)-Funktionen mit zusätzlichen Zero-Trust Enabling-Technologien, einschließlich Zero-Sign-On (ZSO), Multi-Factor-Authentifizierung (MFA) und Mobile Threat Defense (MTD). Über 20.000 Kunden, einschließlich der weltweit größten Finanzinstitute, Nachrichtendienste und anderer stark regulierter Unternehmen, haben sich für MobileIron entschieden, um eine nahtlose und sichere User Experience zu ermöglichen, indem sichergestellt wird, dass nur autorisierte Benutzer, Geräte, Anwendungen und Dienste auf Unternehmensressourcen zugreifen können.

Medienkontakt
Martin Stummer / Maximilian Koob
HBI Helga Bailey GmbH – International PR & MarCom
E-Mail: mobileiron@hbi.de
Tel.: +49-89-99 38 87-34 /-47

Mindpax misst mithilfe eines Armbands in Verbindung mit einer E-Health-Plattform Parameter von PatientInnen mit psychischen Störungen, um Frühwarnsignale an das behandelnde ärztliche Fachpersonal zu senden. Für die Expansion kann sich das Medtech-Startup nun 1,3 Millionen Euro Seed-Finanzierung sichern.

Mindpax hat eine personalisierte E-Health-Plattform mit einer App entwickelt, die die Entwicklung von psychischen Krankheiten kontinuierlich und langfristig über ein Wearable erfassen soll. Das Monitoring objektiver physiologischer Daten, der Stimmung sowie situationsabhängiger Faktoren sind die Basis für die Visualisierung des Tagesablaufs. Diese Daten sollen den PatientInnen und das behandelnde ärztliche Fachpersonal dabei unterstützen, Frühwarnsignale zu erkennen und so die Behandlung anzupassen. Dadurch soll die Dauer einer Krankheitsepisode und eines Krankenhausaufenthaltes reduziert oder ganz vermieden werden.

Expansion in Europa vorantreiben

Für diesen innovativen Ansatz hat das Startup nun 1,3 Millionen Euro von tschechischen Investoren erhalten. Damit sollen die Teams in Prag und München weiter ausgebaut werden, um die Expansion in Europa voranzutreiben. Investiert haben Nation 1, Redwood Capital sowie die privaten Investoren Ivan Hruska und Vlastimil Palata.

Mindpax hat außerdem eine Webseite im Zusammenhang von Covid-19 gestartet, die von PsychologInnen und ÄrztInnen moderiert wird. Sie unterstützen Patienten mit bipolarer Störung und Depression durch kostenlose Psychoedukation gegen Ängste.

Von der erfolgreichen klinischen Studie zur Anwendung

Die Behandlung von bipolaren Störungen ist schwierig und birgt ein hohes Rückfall-Risiko.

„Diese chronische psychische Krankheit ist durch abwechselnde Zustände von Manie und Depression gekennzeichnet, die bis zu mehreren Monaten andauern können. Sie ist mit hohen Selbstmordraten von bis zu zehn Prozent verbunden“, erklärt Dr. Filip Spaniel. Gemeinsam mit Soňa Sikorová, Pavel Nevický, Jan Novák, und Daniel Novák hat er Mindpax gegründet.

Zu Beginn hat das Team untersucht, welche Faktoren die Entwicklung des Krankheitsverlaufs beeinflussen, bei einer bipolaren Erkrankung sind das Parameter wie Schlaf und körperliche Aktivität des Patienten.

„In unserer klinischen Studie mit 350 Patienten konnten wir sehen, wie wir die Entwicklung der Krankheit vorhersagen und dazu beitragen können, sie wirksamer zu behandeln“, sagt Daniel NovákLeiter des Analyseteams.

Klinische Studien mit Schwerpunkt auf bipolaren und psychotischen Störungen

Das Mindpax-Monitoringsystem mit Armband wird in einer Längsschnittforschung in Mitteleuropa eingesetzt. An der AKTIBIPO400-Studie in Zusammenarbeit mit dem Nationalen Institut für psychische Gesundheit (NUDZ) sind 350 bipolare PatientInnen und mehr als 100 PsychiaterInnen aus der gesamten Tschechischen Republik und der Slowakei beteiligt. 200 PatientInnen haben bereits die volle Studiendauer von 18 Monaten abgeschlossen, 50 weitere folgen in den nächsten sechs Monaten. Im Laufe des Jahres 2020 werden weitere klinische Studien mit Schwerpunkt auf bipolaren und psychotischen Störungen durchgeführt. Dafür kooperiert Mindpax nach eigenen Angaben mit spezialisierten Kliniken und Universitäten in Deutschland, Großbritannien, Belgien, Frankreich, USA und Kanada.

NEW YORK, April 23, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium Capital, providing for the purchase and sale of 1,764,706 shares of common stock at a price of $8.50 per share in a registered direct offering.

The offering is expected to close on or about April 27, 2020, subject to satisfaction of customary closing conditions. Net proceeds of the offering, after placement agent fees are expected to be approximately $14 million. Immunic intends to use the proceeds to fund the ongoing clinical development of the Company’s three small molecule products: IMU-838, IMU-935 and IMU-856, and for other general corporate purposes, including to investigate IMU-838, the Company’s lead asset, as a potential oral treatment option for COVID-19.

Roth Capital Partners is acting as sole agent in connection with the offering.

The shares of common stock were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-225230), which was declared effective by the United States Securities and Exchange Commission (SEC) on June 13, 2018.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock will be filed by Immunic with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC’s website at www.sec.gov or from Roth Capital Partners, 888 San Clemente Drive, Suite 400, Newport Beach, CA 92660, (800) 678-9147.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic’s lead development program, IMU-838, is in phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial considered in Crohn’s disease. The company is also investigating IMU-838 as a potential treatment option for COVID-19. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s three development programs and the targeted diseases; the potential for IMU-838 to safely and effectively target diseases; preclinical and clinical data for IMU-838; the timing of current and future clinical trials; the potential for IMU-838 as a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections causing coronavirus disease 2019 (COVID-19) and other viruses and any clinical trials, collaborations and approvals relating to such potential treatment; the nature, strategy and focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.immunic-therapeutics.com/sec-filings and on request from Immunic. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

 

Contact Information

Immunic, Inc.
Jessica Breu
Manager Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

Or

Rx Communications Group
Melody Carey
+1-917-322-2571
immunic@rxir.com

Zurich, Switzerland and Munich, Germany, April 1, 2020 – Neurimmune AG and Ethris GmbH announced today an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19. The collaboration brings together Neurimmune’s expertise in developing human antibodies based on high-throughput immunoglobulin sequence analyses from Covid-19 patients who have recovered from the disease with Ethris’ proprietary and unique pulmonary SNIM®RNA therapeutics platform. Both companies will work together to rapidly develop an immunotherapy designed to produce therapeutic antibodies directly in the lungs of affected patients.

Enabled by Ethris’ mRNA technology, the production of specific, neutralizing antibodies directly in patients‘ lungs provides the opportunity to significantly impact the viral lung disease that is the primary driver of morbidity and mortality. The planned treatment could be effective in all Covid-19 patients.

Neurimmune is identifying human anti-SARS-CoV-2 antibodies from the immune cells of recovered Covid19 patients using its RTMTM Technology platform. Potent neutralizing antibodies will be translated into therapeutic SNIM®RNA products for inhalation. Based on current development plans, the first product candidate is expected to begin clinical testing in the fourth quarter of 2020, pending regulatory approval.

“The speed and precision that mRNA technologies provide make them well-suited for designing therapeutic candidates to treat the Covid-19 pandemic. We have built a strong platform for developing potent mRNAs to treat pulmonary disorders and local delivery in the lung may provide significant therapeutic benefits. By combining our approach with Neurimmune’s proven human antibody technology, we are well-positioned to expediently develop a treatment that could save lives,” said Ethris CEO, Dr. Gita Dittmar.

“Covid-19 patients with lung disease require a safe and effective therapy urgently. Together, we aim to develop this novel treatment at the highest speed possible. Time is of the essence.” said Roger Nitsch, Neurimmune’s CEO.

Jan Grimm, CSO of Neurimmune added: “With Ethris‘ pulmonary SNIM®RNA technology we can leverage state-of-the-art technology to express human SARS-CoV-2 neutralizing antibodies directly in the lung to rapidly achieve effective pulmonary antibody concentrations.”

Dr. Carsten Rudolph, CSO of Ethris added: “This collaborative effort is underscored by the immense need for a treatment and our combined commitment to put a therapy into the hands of the doctors and nurses who are fighting this disease across the globe. We are two companies among many that are applying innovation and speed to make a valuable contribution to curb this pandemic, and we thank our partners at Neurimmune for joining us for this effort.“

Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration. The companies intend to initiate manufacturing of the drug product for clinical trials this summer, and will inform about progress made as the collaboration advances.

 

About Neurimmune 
Neurimmune AG is a leading biopharmaceutical company in the field of human antibody therapeutics. Six programs are currently in clinical study phases, including Aducanumab that concluded phase III clinical trials (licensed to Biogen Inc., Cambridge, Mass. USA). Neurimmune’s technology focusses on the cloning of authentic human antibodies from healthy elderly subjects, or from patients who recovered from disease, by translating the immune memory of functionally active antibodies into transformative immunotherapeutics. This technology platform is known as RTMTM (Reverse Translational Medicine) technology.
Besides Covid-19, Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer’s and Parkinson’s diseases, ALS, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune has three additional antibody programs in preclinical development, and expanded its treatment modalities by programs involving the vectorized expression of human antibody genes and a small molecule program. 
www.neurimmune.com/

About Ethris 
Ethris is paving a new path from genes to therapeutic proteins using its proprietary messenger RNA technology platform, which enables the discovery, design and development of transcript therapies that drive the production of therapeutic proteins within patients’ cells and tissues. Ethris’ remains a global leader in delivery of mRNA directly to the respiratory system via nebulization. The company’s lead program ETH42 is in preclinical development for treatment of a rare pulmonary disease, primary ciliary dyskinesia, and the company collaborates with AstraZeneca in the fields of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. For more information, visit www.ethris.com.

 

For Neurimmune, please contact: 

Neurimmune AG 
Dr. Fabian Buller, CBO of Neurimmune
Tel.: +41 44 755 4623 
E-Mail: fabian.buller@neurimmune.com

Media: 
Martin Meier-Pfister, IRF
Tel.: +41 43 244 81 40 
E-Mail: media@neurimmune.com

For Ethris, please contact: 

Ethris GmbH 
Ms. Dagmar Ackerknecht
Tel.: +49-(0)89-8955-788 10 
E-Mail: info@ethris.com 

Trophic Communications 
Dr. Jacob Verghese 
Tel.: +49 151 7441 6179 
E-Mail: verghese@trophic.eu

Investment to help accelerate the expansion of SimScale’s cloud-based engineering simulation platform for customers

Munich, Germany – January 30, 2020 –  SimScale, the provider of the world’s first production-ready SaaS application for engineering simulation, today announced that it has closed €27 million in Series C funding. Global venture capital and private equity firm Insight Partners led the round, with participation from existing investors: Earlybird, Union Square Ventures, June Fund, Vito Ventures, Bayern Kapital, and High-Tech Gründerfonds. SimScale’s latest funding round follows a prior round in 2017 led by June Fund.   

SimScale will use this investment to accelerate the expansion of its cloud-based computer-aided engineering (CAE) platform for customers and grow global operations. SimScale provides computational fluid dynamics (CFD) and finite element analysis (FEA) simulation via the cloud, eliminating the hurdles that often accompany traditional, on-premises simulation tools. By leveraging the power of the cloud, SimScale helps customers cut the cost of expensive hardware and software maintenance fees. Also, SimScale offers parallel processing of multiple designs, allowing customers to quickly identify those that are best-performing. Engineers seeking to make their design processes more iterative can simulate their designs using only a standard web browser.

“SimScale’s platform has minimized the barriers that prevented many engineering firms from using or scaling simulation,” said Joshua Fredberg, CAE software veteran and operating partner at Insight Partners, who joined SimScale’s board of directors. “Simulating designs is now possible for engineers who previously believed such capabilities were out of reach. We believe SimScale is well positioned to transform not only who uses simulation, but how it is used across several engineering disciplines.” Insight Partners is a leader in investing in changemakers who create transformational software and are experiencing monumental growth. Insight has invested in more than 300 companies and participated in over 40 IPOs. As a growth equity investor, Insight is focused on providing capital and operating expertise to the best software companies and helping them scale.

“SimScale is proud to have brought cloud-based simulation to engineering teams worldwide,” said David Heiny, CEO of SimScale. “We’re thrilled to welcome the team from Insight Partners to SimScale’s journey. This investment marks the next phase of SimScale’s growth, as we empower more customers to produce better designs faster.”

 

About SimScale:
Founded in 2012 with offices in Munich, New York, and Boston, SimScale is the world’s first production-ready SaaS application for simulation. By providing instant access to computational fluid dynamics (CFD) and finite element analysis (FEA) to over 150,000 users, SimScale has moved high-fidelity physics simulation technology from a complex and cost-prohibitive desktop application to a user-friendly cloud application accessible via a subscription-based pricing model. For more information, visit www.simscale.com/.

Über Bayern Kapital:
Die Bayern Kapital GmbH mit Sitz in Landshut wurde auf Initiative der Bayerischen Staatsregierung 1995 als 100-prozentige Tochtergesellschaft der LfA Förderbank Bayern gegründet. Bayern Kapital stellt als Venture-Capital-Gesellschaft des Freistaats Bayern den Gründern innovativer High-Tech-Unternehmen und jungen, innovativen Technologieunternehmen in Bayern Beteiligungskapital zur Verfügung. Bayern Kapital verwaltet derzeit elf Beteiligungsfonds mit einem Beteiligungsvolumen von rund 385 Millionen Euro. Bislang hat Bayern Kapital rund 308 Millionen Euro Beteiligungskapital in 272 innovative technologieorientierte Unternehmen aus verschiedensten Branchen investiert, darunter Life Sciences, Software & IT, Werkstoffe & Neue Materialien, Nanotechnologie sowie Umwelttechnologie. So sind in Bayern über 5000 Arbeitsplätze dauerhaft in zukunftsfähigen Unternehmen entstanden. www.bayernkapital.de


Kontakt

SimScale
Jenifer Silverstein
Vice President of Marketing, SimScale
E-Mail: jsilverstein@simscale.com
Tel.: +49 89 809 1327 xt 65

Bayern Kapital
IRA WÜLFING KOMMUNIKATION GmbH
Ira Wülfing / Jan Dermietzel
E-Mail: bayernkapital@wuelfing-kommunikation.de
Tel.: +49 89 2000 30-30

Landshut/München, 03. Februar 2020. Bayern Kapital beteiligt sich im Rahmen einer Serie-B-Runde erneut an der TriOptoTec GmbH aus Regensburg. Das Start-up hat auf Basis der sogenannten Photodynamik ein innovatives Verfahren entwickelt, um jegliche Arten von Oberflächen – insbesondere in Krankenhäusern oder Altenheimen – dauerhaft und umweltschonend zu desinfizieren. Dadurch kann die Belastung mit Keimen um bis zu 99,9999 Prozent reduziert werden. Weitere Investoren in dieser Runde in Gesamthöhe von zwei Millionen Euro sind CD-Venture sowie mehrere Business Angels. Mit den neuen finanziellen Mitteln möchte das junge Unternehmen die Vermarktung und Vertriebsaktivitäten für sein Desinfektionsprodukt DYPHOX vorantreiben. Bayern Kapital hatte sich bereits im Jahr 2017 gemeinsam mit mehreren Business Angels an der Serie-A-Runde des Start-ups beteiligt.

TriOptoTec mit Sitz in Regensburg und aktuell 10 Mitarbeitern ist eine Ausgründung des dortigen Universitätsklinikums Regensburg (UKR). Die ursprünglich aus der Krebstherapie (weißer Hautkrebs) stammende Technologie hatte das 2010 gegründete Start-up weiterentwickelt, um die desinfizierende Wirkung auch in anderen Bereichen zur Anwendung zu bringen. Unter dem Namen DYPHOX hat TriOptoTec nun ein antimikrobielles Wirkstoffsystem auf Basis der sogenannten Photodynamik auf den Markt gebracht. Die Wirkweise: Ein sogenannter photodynamischer Katalysator wird als Zusatz zu Oberflächenlacken oder -farben beigemischt. Durch die Verbindung mit Lichtenergie – gleich ob natürliches oder künstliches Licht – verwandelt dieser Zusatz den Sauerstoff aus der Umgebungsluft in einen hochreaktiven Sauerstoff. Dieser zerstört Mikroorganismen direkt und schnell, was deren Zahl auf Oberflächen um bis zu 99,9999 Prozent reduzieren kann und somit einen wirkungsvollen Schutz gegen Infektionen bietet.

Die Wirksamkeit des für Menschen vollkommen ungiftigen Verfahrens wurde in einer aktuellen Studie am UKR sowie am Caritas-Krankenhaus St. Josef in Regensburg getestet und in der international renommierten Fachzeitschrift Journal of Hospital Infection publiziert. Für die Technologie hält TriOptoTec aktuell sieben Patente. Hauptanwendungsgebiet sind Krankenhäuser, die generell daran interessiert sind, die Keimbelastung so gering wie möglich zu halten – gerade in Hinblick auf multiresistente Keime. Jedes Jahr infizieren sich nach Schätzungen rund 600.000 Patienten in deutschen Krankenhäusern mit Keimen, wovon bei rund 15.000 Patienten die Infektionen tödliche Folgen haben. Nach Schätzungen wäre mindestens ein Drittel dieser Fälle mit entsprechender Hygiene oder wirkungsvoller Desinfektion vermeidbar. DYPHOX wird entweder ab Werk oder nachträglich beispielsweise auf Krankenhausbetten, -tischen oder bei –sanitärprodukten aufgebracht.

Xaver Auer, Geschäftsführer von TriOptoTec sagt: „Trotz umfangreicher, standardiserter Hygienemassnahmen sind Keime nachwievor ein großes Problem in Krankenhäusern und im gesamten Gesundheitsbereich. Wir sind überzeugt, dass unsere völlig ungiftige Technologie entscheidend dabei helfen kann, viele Infektionen zu vermeiden und damit das Gesundheitswesen ein Stück weit sicherer zu machen. Nachdem wir das Produkt zur Marktreife entwickelt und die Wirksamkeit nachgewiesen haben, wollen wir nun die Vermarktung und Vertriebsaktivitäten vorantreiben.“

Dr. Georg Ried, Geschäftsführer von Bayern Kapital, sagt: „Die Technologie adressiert ein großes Problem und hat seine Wirksamkeit bereits eindrucksvoll unter Beweis gestellt. Was besonders vielversprechend ist: DYPHOX ist leicht zu verarbeiten und kann neben dem Gesundheitswesen auch in vielen anderen Bereichen – von der Industrie bis hin zu Lebensmittelverpackung – angewendet werden. Daher verspricht die Technologie von TriOptoTec ein großes Marktpotential.“

Weiterführende Informationen zur Studie finden Sie unter folgendem Link:
https://www.ukr.de/service/aktuelles/06094.php


Über die TriOptoTec GmbH:

TriOptoTec mit Sitz in Regensburg und aktuell 10 Mitarbeitern ist eine Ausgründung des dortigen Universitätsklinikums UKR. Die ursprünglich aus der Krebstherapie (weißer Hautkrebs) stammende Technologie wurde in der Arbeitsgruppe um Prof. Dr. Wolfgang Bäumler weiter erforscht, um sie auch gegen krankmachende Keime zur Anwendung bringen zu können. Das 2017 gegründete Start-up TriOptoTec hat die Technologie weiterentwickelt und unter dem Namen DYPHOX nun ein dauerhaft aktives antimikrobielles Wirkstoffsystem auf Basis der sogenannten Photodynamik auf den Markt gebracht. DYPHOX kann als Additiv in Lacke, Drucklacke, Wandfarben, Silikone und Flüssigkeiten eingebracht werden oder ist als Wischtuch, Sprüh- und Wischlösung für eine nachträgliche Beschichtung von Oberflächen erhältlich. Diese permanente antimikrobielle Wirkung auf Oberflächen jeglicher Art schließt Hygienelücken dauerhaft und reduziert das Risiko der Weitergabe von Keimen signifikant. Mit Xaver Auer verfügt TriOptoTec über einen erfahrenen CEO, um das Unternehmen zu einem der führenden Unternehmen für antimikrobielle Oberflächentechnologien aufzubauen. DYPHOX wird unter anderem im Gesundheitswesen, im öffentlichen Bereich und Bürogebäuden, der Medizintechnik, der Verpackungsindustrie, dem Transportwesen, der Lebensmittelindustrie, der Gastronomie und im Maschinenbau eingesetzt.

Über Bayern Kapital:

Die Bayern Kapital GmbH mit Sitz in Landshut wurde auf Initiative der Bayerischen Staatsregierung 1995 als 100-prozentige Tochtergesellschaft der LfA Förderbank Bayern gegründet. Bayern Kapital stellt als Venture-Capital-Gesellschaft des Freistaats Bayern den Gründern innovativer High-Tech-Unternehmen und jungen, innovativen Technologieunternehmen in Bayern Beteiligungskapital zur Verfügung. Bayern Kapital verwaltet derzeit elf Beteiligungsfonds mit einem Beteiligungsvolumen von rund 325 Millionen Euro. Bislang hat Bayern Kapital rund 305 Millionen Euro Beteiligungskapital in über 270 innovative technologieorientierte Unternehmen aus verschiedensten Branchen investiert, darunter Life Sciences, Software & IT, Werkstoffe & Neue Materialien, Nanotechnologie sowie Umwelttechnologie. So sind in Bayern über 7.500 Arbeitsplätze dauerhaft in zukunftsfähigen Unternehmen entstanden. www.bayernkapital.de


Pressekontakt Bayern Kapital:

IWK Communication Partner
Benedikt Nesselhauf
Tel.: +49 89 2000 30-30
E-Mail: bayernkapital@iwk-cp.com

 

Private-Equity Firma investiert zur Beschleunigung von Innovation und internationaler Expansion in eines der am schnellsten wachsenden Echtzeit-Rendering-SaaS-Unternehmen der AEC Industrie 

Karlsruhe, Deutschland (4. Februar 2020) — Enscape GmbH, ein führender Anbieter von Echtzeit-3D-Rendering- und Visualisierungsprodukten für die Architektur-, Ingenieur- und Bauindustrie (AEC), und der Technologieinvestor LEA Partners gaben heute eine strategische Partnerschaft zur Beschleunigung des Wachstums von Enscape auf dem globalen AEC-Markt bekannt. Die beiden Gründer Thomas Willberger und Moritz Luck sowie der High-Tech Gründerfonds (HTGF) als bestehender Investor bleiben weiterhin signifikant an Enscape beteiligt. 

„LEA Partners hat uns durch ihre Professionalität als fokussierter Technologieinvestor überzeugt. Das tiefe Verständnis des Software-as-a-Service (SaaS)-Markts und ihr globales Netzwerk machen LEA Partners zum idealen Partner für die nächste Wachstumsphase von Enscape“, sagt Thomas Willberger, CEO und Mitgründer von Enscape. „Wir wollen Produktinnovationen und die internationale Expansion beschleunigen, mit dem Ziel, der Standard im Echtzeit-Rendering für den globalen BIM-Markt zu werden.“

Nach einem kürzlich erschienenen Bericht von ResearchAndMarkets.com wird der weltweite Building Information Modeling (BIM) -Markt von 4,9 Milliarden USD im Jahr 2019 bis 2024 auf 8,9 Milliarden USD wachsen. 

„Mit der proprietären Echtzeit-Rendering-Technologie, der hohen Benutzerfreundlichkeit und dem ausgeprägten Endkunden-Support ist Enscape einzigartig positioniert, um von der steigenden Durchdringung von BIM zu profitieren“, sagt Christian Roth, Managing Partner bei LEA Partners. „Das Unternehmen hat seit seiner Gründung ein enormes organisches Wachstum erlebt. Wir freuen uns darauf, Enscape dabei zu unterstützen, in neue Segmente und Märkte zu expandieren.“

Seit der Markteinführung seiner Produkte 2017 hat Enscape ein rasantes Wachstum erlebt und dabei

  • Echtzeit-Verbindungen mit den wichtigsten BIM-Planungs- und Designprogrammen, darunter Trimble SketchUp™ und Autodesk Revit ™, Robert McNeel & Associates Rhinoceros®, Nemetschek’s ArchiCAD® und bald auch Vectorworks® entwickelt, 
  • mehr als 250.000 Software-Installationen weltweit, darunter bei 85 der weltweit führenden TOP100-Architekturbüros wie KPF, Foster+Partner, NBBJ und Aedas erreicht,
  • seine SaaS-Umsätze im Durchschnitt um über 100 % pro Jahr gesteigert und
  • die Anzahl der Mitarbeiter am Hauptsitz in Deutschland und in den USA mehr als verdoppelt.

Über Enscape
Enscape mit Sitz in Karlsruhe wurde 2017 gegründet und hat sich seither in der internationalen Architecture, Engineering und Construction (AEC) Branche etabliert. Das Produkt ermöglicht Anwendern hochwertige 3D Echtzeitvisualisierungen auf Basis ihrer bereits vorhandenen Daten zu erstellen. Ebenso können Videos, Panoramen oder VR Simulationen abgeleitet werden. Unternehmen aus über 80 Ländern und 85% der international renommierten TOP100 Architekturbüros verwenden Enscape. 

Über LEA Partners
LEA Partners unterstützt als unternehmerischer Eigenkapitalpartner Gründer und Management-Teams in unterschiedlichen Entwicklungsphasen bei ihrem Wachstum und dem Erreichen einer führenden Marktposition. Mit Sitz in Karlsruhe, einem der größten Technologie Cluster Europas, hat LEA Partners seit 2002 Investments in zahlreiche Technologieunternehmen betreut. Mit zwei Investitionsvehikeln für alle Unternehmensphasen und einem starken Netzwerk aus operativen Sektor-Experten sowie strategischen Partnern kann LEA Partners substantielle Mehrwerte zur Entwicklung von Technologieunternehmen beisteuern.


Kontakt:

LEA Partners GmbH 
E-Mail: press@leapartners.de
Phone:  +49 721 13 208 700

Enscape GmbH
Madeleine Clark
E-Mail: press@enscape3d.com
Phone:    +49 721 132 060

2020